Human biokinetics of injected bismuth-207

A healthy male volunteer received an intravenous injection of 207Bi as citrate. Levels of the tracer in blood and in excretion samples, and its retention and distribution within the body, were investigated by appropriate radioactivity measurements. Levels in blood fell very rapidly, with only 1% of the injection remaining at 7 h and only ca. 0.1% at 18 days. There was rapid initial excretion, with 55% lost during the first 47 h, principally in urine; however, longer-term losses were much slower and 0.6% remained in the body at 924 days, when the contemporary rate of loss implied a half-life of 1.9 years. Integration of the retention pattern suggested that steady exposure to bismuth compounds could lead ultimately to a body content of 24 times the daily systemic uptake. The largest organ deposit was in the liver, which after 3 days contained ca. 60% of the contemporary whole body content, consistent with reports of hepatotoxicity. These findings differ markedly from the metabolic model for bismuth proposed by the International Commission on Radiological Protection, which envisages a terminal half-life in the body of only 5 days and kidney as the site of highest deposition.

Human metabolism of aluminium-26 and gallium-67 injected as citrates

1 26Al and 67Ga were given as citrates to a healthy male volunteer by intravenous injection. The retention of both tracers was studied by body radioactivity measurement. Levels in blood and excreta were determined by y-ray spectrometry and/or accelerator mass spectrometry. 2 More than half of the 26Al had left the blood after 15 min and the decline continued, leaving <1% in blood after 2 d; the losses occurred both to renal excretion and through uptake by other compartments. Estimated excre tion up to 13 d was 83% (urine) and 1.8% (faeces). Whole-body retention of 15% at 13 d declined to ∼4% at 1178 d, when the daily reduction corresponded to a bio logical half-life of 7 y, suggesting that sustained intake of dietary aluminium may lead to a progressively increas ing internal deposit. 3 The metabolism of 67Ga differed markedly from that of 26Al in all aspects studied.

Plasma Hydrazine Concentrations in Man after Isoniazid and Hydralazine Administration

1 By using a specific sensitive stable-isotope dilution gas chromatography-mass spectrometry (GC-MS) assay, hydrazine was detected in the plasma of eight healthy male volunteer subjects taking isoniazid (300 mg daily) for 2 weeks. 2 Accumulation of hydrazine occurred in slow-acetylator phenotypes. 3 Hydrazine was also detected in the plasma of eight out of 14 hypertensive patients treated chronically with hydralazine (200 mg daily). 4 However, the concentrations of hydrazine observed were much lower than in the isoniazid study and were close to the limit of detection. 5 As hydrazine is hepatotoxic, mutagenic and carcinogenic in animals, its presence in human plasma has important toxicological implications.